Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model.
Ataluren
Conceptual model
Duchenne muscular dystrophy
Nonsense mutation
Qualitative
Symptoms
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
21 Aug 2021
21 Aug 2021
Historique:
received:
09
02
2021
accepted:
07
07
2021
entrez:
22
8
2021
pubmed:
23
8
2021
medline:
23
8
2021
Statut:
epublish
Résumé
Duchenne muscular dystrophy is a rare genetic neuromuscular disorder, which can result in early death due to disease progression. Ataluren is indicated for the treatment of nonsense mutation Duchenne muscular dystrophy, in ambulatory individuals aged two years and older. This study explored the symptoms and impacts of nonsense mutation Duchenne muscular dystrophy and experience with ataluren. Qualitative interviews were conducted with caregivers in the UK. Interviews were conducted by telephone, were recorded and transcribed. Data were analysed using thematic analysis and saturation was recorded. Ten interviews were conducted with parents of individuals aged 4-19 years. Key symptoms included muscle weakness and muscle breakdown, which were associated with limitations in physical function and pain. These impacted individuals' daily activities, social activities and emotional wellbeing. These concepts and relationships were illustrated in a conceptual model, along with positive and negative moderating factors. Experience with ataluren and changes since initiation with treatment were discussed. Individuals with nonsense mutation Duchenne muscular dystrophy experience a range of interrelated symptoms and functional issues which impact their broader health-related quality of life. Treatments which address this high unmet need have the potential to improve the health-related quality of life of these individuals.
Sections du résumé
BACKGROUND
BACKGROUND
Duchenne muscular dystrophy is a rare genetic neuromuscular disorder, which can result in early death due to disease progression. Ataluren is indicated for the treatment of nonsense mutation Duchenne muscular dystrophy, in ambulatory individuals aged two years and older. This study explored the symptoms and impacts of nonsense mutation Duchenne muscular dystrophy and experience with ataluren.
METHODS
METHODS
Qualitative interviews were conducted with caregivers in the UK. Interviews were conducted by telephone, were recorded and transcribed. Data were analysed using thematic analysis and saturation was recorded.
RESULTS
RESULTS
Ten interviews were conducted with parents of individuals aged 4-19 years. Key symptoms included muscle weakness and muscle breakdown, which were associated with limitations in physical function and pain. These impacted individuals' daily activities, social activities and emotional wellbeing. These concepts and relationships were illustrated in a conceptual model, along with positive and negative moderating factors. Experience with ataluren and changes since initiation with treatment were discussed.
CONCLUSION
CONCLUSIONS
Individuals with nonsense mutation Duchenne muscular dystrophy experience a range of interrelated symptoms and functional issues which impact their broader health-related quality of life. Treatments which address this high unmet need have the potential to improve the health-related quality of life of these individuals.
Identifiants
pubmed: 34420127
doi: 10.1186/s41687-021-00341-x
pii: 10.1186/s41687-021-00341-x
pmc: PMC8380095
doi:
Types de publication
Journal Article
Langues
eng
Pagination
75Informations de copyright
© 2021. The Author(s).
Références
Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):269-81
pubmed: 20545592
Health Qual Life Outcomes. 2020 Aug 3;18(1):263
pubmed: 32746836
Lancet. 2002 Feb 23;359(9307):687-95
pubmed: 11879882
Cochrane Database Syst Rev. 2016 May 05;(5):CD003725
pubmed: 27149418
Mol Ther. 2011 May;19(5):830-40
pubmed: 21468001
J Med Genet. 2016 Mar;53(3):145-51
pubmed: 26754139
BMJ Open. 2019 Mar 9;9(3):e023685
pubmed: 30852532
Eur J Epidemiol. 2020 Jul;35(7):643-653
pubmed: 32107739
Eur J Paediatr Neurol. 2016 Jul;20(4):630-8
pubmed: 27053141
Orphanet J Rare Dis. 2017 Apr 26;12(1):79
pubmed: 28446219
J Comp Eff Res. 2019 Oct;8(14):1187-1200
pubmed: 31414621